Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
November 10 2022 - 6:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the pharmaceutical research,
development and manufacturing of rare cannabinoids and cannabinoid
analogs, announces that InMed’s CEO Eric A. Adams and Eric Hsu, SVP
of Preclinical Research and Development will present at Tribe
Public’s Webinar Presentation and Q&A Event titled
"Exploring the Neuroprotective Qualities of Rare
Cannabinoids
." The Event is scheduled to begin at
8.30am Pacific/11.30am Eastern on November 17, 2022.
To register to join the complimentary, ZOOM
webinar-based event, please visit Tribe Public LLC at
INMNOV17.TribePublic.com. Once registered, participants may begin
forwarding their questions for InMed’s management to Tribe Public
at research@tribepublic.com or share their questions via
the ZOOM chat feature during the event. Tribe Public’s Managing
Member, John F. Heerdink, Jr., will host the event and relay all
questions to management.
About InMed; InMed
Pharmaceuticals is a global leader in the pharmaceutical research,
development and manufacturing of rare cannabinoids and cannabinoid
analogs, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We
also have significant know-how in developing proprietary
manufacturing approaches to produce cannabinoids for various market
sectors. For more information, visit www.inmedpharma.com and
www.baymedica.com.
About Tribe Public LLCTribe
Public LLC is a San Francisco, CA-based organization that hosts
complimentary worldwide webinar & meeting events in the U.S.
Tribe’s events focus on issues that the Tribe’s members care about
with an emphasis on hosting management teams and experts from
publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress, and plans. Tribe members primarily include
Institutions, Family Offices, Portfolio Managers, Registered
Investment Advisors, Accredited Investors, Sell Side Analysts, and
members of media. Tribe Members are encouraged to express their
interest in speakers at the Tribe Public website via the Tribe’s
FREE “Wish List” process. Visit Tribe Public’s
Website http://www.tribepublic.com/ to join the Tribe and
express your interests today.
Investor Contact: Colin ClancyVice President,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: the potential impact of cannabinoids on
neurodegenerative diseases and being a global leader in the
research, development, manufacturing and commercialization of rare
cannabinoids; and delivering new treatment alternatives to patients
that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jun 2024 to Jul 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jul 2023 to Jul 2024